Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Abstract The past decade has witnessed the explosive development of cancer immunotherapies. Nevertheless, low immunogenicity, limited specificity, poor delivery efficiency, and off‐target side effects remain to be the major limitations for broad implementation of cancer immunotherapies to patient be...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-05-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202200027 |
| _version_ | 1811257086468685824 |
|---|---|
| author | Shaobo Ruan Yuanyu Huang Mei He Huile Gao |
| author_facet | Shaobo Ruan Yuanyu Huang Mei He Huile Gao |
| author_sort | Shaobo Ruan |
| collection | DOAJ |
| description | Abstract The past decade has witnessed the explosive development of cancer immunotherapies. Nevertheless, low immunogenicity, limited specificity, poor delivery efficiency, and off‐target side effects remain to be the major limitations for broad implementation of cancer immunotherapies to patient bedside. Encouragingly, advanced biomaterials offering cell‐specific modulation of immunological cues bring new solutions for improving the therapeutic efficacy while relieving side effect risks. In this review, focus is given on how functional biomaterials can enable cell‐specific modulation of cancer immunotherapy within the cancer‐immune cycle, with particular emphasis on antigen‐presenting cells (APCs), T cells, and tumor microenvironment (TME)‐resident cells. By reviewing the current progress in biomaterial‐based cancer immunotherapy, here the aim is to provide a better understanding of biomaterials’ role in targeting modulation of antitumor immunity step‐by‐step and guidelines for rationally developing targeting biomaterials for more personalized cancer immunotherapy. Moreover, the current challenge and future perspective regarding the potential application and clinical translation will also be discussed. |
| first_indexed | 2024-04-12T17:51:12Z |
| format | Article |
| id | doaj.art-b14da6b7bcec4fb3a54172189c7ead26 |
| institution | Directory Open Access Journal |
| issn | 2198-3844 |
| language | English |
| last_indexed | 2024-04-12T17:51:12Z |
| publishDate | 2022-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj.art-b14da6b7bcec4fb3a54172189c7ead262022-12-22T03:22:30ZengWileyAdvanced Science2198-38442022-05-01916n/an/a10.1002/advs.202200027Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer ImmunotherapyShaobo Ruan0Yuanyu Huang1Mei He2Huile Gao3Advanced Research Institute of Multidisciplinary Science Beijing Institute of Technology Beijing 100081 ChinaAdvanced Research Institute of Multidisciplinary Science Beijing Institute of Technology Beijing 100081 ChinaCollege of Pharmacy University of Florida Gainesville FL 32610 USAWest China School of Pharmacy Sichuan University Chengdu 610041 ChinaAbstract The past decade has witnessed the explosive development of cancer immunotherapies. Nevertheless, low immunogenicity, limited specificity, poor delivery efficiency, and off‐target side effects remain to be the major limitations for broad implementation of cancer immunotherapies to patient bedside. Encouragingly, advanced biomaterials offering cell‐specific modulation of immunological cues bring new solutions for improving the therapeutic efficacy while relieving side effect risks. In this review, focus is given on how functional biomaterials can enable cell‐specific modulation of cancer immunotherapy within the cancer‐immune cycle, with particular emphasis on antigen‐presenting cells (APCs), T cells, and tumor microenvironment (TME)‐resident cells. By reviewing the current progress in biomaterial‐based cancer immunotherapy, here the aim is to provide a better understanding of biomaterials’ role in targeting modulation of antitumor immunity step‐by‐step and guidelines for rationally developing targeting biomaterials for more personalized cancer immunotherapy. Moreover, the current challenge and future perspective regarding the potential application and clinical translation will also be discussed.https://doi.org/10.1002/advs.202200027biomaterialscancer immunotherapydrug deliverytargeting modulationvaccines |
| spellingShingle | Shaobo Ruan Yuanyu Huang Mei He Huile Gao Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy Advanced Science biomaterials cancer immunotherapy drug delivery targeting modulation vaccines |
| title | Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy |
| title_full | Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy |
| title_fullStr | Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy |
| title_full_unstemmed | Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy |
| title_short | Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy |
| title_sort | advanced biomaterials for cell specific modulation and restore of cancer immunotherapy |
| topic | biomaterials cancer immunotherapy drug delivery targeting modulation vaccines |
| url | https://doi.org/10.1002/advs.202200027 |
| work_keys_str_mv | AT shaoboruan advancedbiomaterialsforcellspecificmodulationandrestoreofcancerimmunotherapy AT yuanyuhuang advancedbiomaterialsforcellspecificmodulationandrestoreofcancerimmunotherapy AT meihe advancedbiomaterialsforcellspecificmodulationandrestoreofcancerimmunotherapy AT huilegao advancedbiomaterialsforcellspecificmodulationandrestoreofcancerimmunotherapy |